GlassScriptPhysician profile
Hillary Klein Beberman
NPI 1699726802
$3,471.18
in general payments reported to CMS, 2019-2025
33 companies · $986 in 2025
The $986 reported for 2025 was more than what 86% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $357 · 2022: $536 · 2023: $771 · 2024: $821 · 2025: $986.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,578.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,578.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $482.04 | 2021-2025 | Ubrelvy |
| Amgen INC. | $450.71 | 2022-2025 | Otezla, Repatha, Evenity |
| Lilly USA, LLC | $390.05 | 2022-2025 | Mounjaro, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $358.02 | 2021-2025 | Jardiance, Synjardy, Ofev |
| Novo Nordisk INC | $220.83 | 2022-2025 | Wegovy, Saxenda, Ozempic |
| Pfizer INC. | $140.48 | 2021-2025 | |
| Genzyme Corporation | $125.72 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $104.01 | 2021-2025 | Airsupra, Breztri |
| Baxter Healthcare | $84.92 | 2025 | Hillrom - Connex Spot Monitor |
| Takeda Pharmaceuticals U.S.A., INC. | $84.41 | 2022-2023 | Trintellix |
| Novartis Pharmaceuticals Corporation | $82.98 | 2021-2023 | |
| Glaxosmithkline, LLC. | $78.57 | 2021-2025 | Arexvy, Shingrix |
| Sumitomo Pharma America, INC. | $78.12 | 2025 | Gemtesa |
| Acerus Pharmaceuticals Corporation | $75.30 | 2021-2022 | |
| Eisai INC. | $68.47 | 2021-2024 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $67.40 | 2023-2024 | Veozah, Myrbetriq |
| Sanofi Pasteur INC. | $61.63 | 2023-2024 | |
| Vivus LLC | $54.36 | 2021-2024 | Qsymia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $49.25 | 2022-2025 | Xifaxan |
| Inspire Medical Systems, INC. | $48.43 | 2025 | Inspire |
| Abbott Laboratories | $48.36 | 2023-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Axsome Therapeutics, INC. | $45.62 | 2023 | Auvelity |
| Ibsa Pharma INC. | $45.53 | 2022-2023 | Tirosint, Licart |
| Azurity Pharmaceuticals, INC. | $44.43 | 2024 | Edarbyclor |
| Antares Pharma, INC. | $31.54 | 2024-2025 | Xyosted |
| Cmp Pharma, INC. | $24.63 | 2023 | Norliqva, Tadliq, Carospir |
| Tolmar, INC. | $22.50 | 2025 | Jatenzo |
| Cleerly, INC. | $21.61 | 2025 | Cleerly Ischemia, Cleerly Labs |
| Janssen Pharmaceuticals, INC | $20.40 | 2021 | |
| Phadia US INC. | $17.56 | 2023 | Immunocap |
| Arbor Pharmaceuticals, INC. | $15.71 | 2022 | |
| Currax Pharmaceuticals LLC | $14.44 | 2021 | |
| Genentech USA, INC. | $13.15 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hillary Beberman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.